Tag

Aducanumab

All articles tagged with #aducanumab

health1 year ago•7 min saved

"Seven Years on Now-Defunct Alzheimer's Medication 'Paused' My Disease: Without It, No Hope"

Geri Taylor, a former executive, experienced cognitive decline and was diagnosed with early-stage Alzheimer's. She participated in a trial for the now-discontinued drug aducanumab, which seemed to pause her cognitive decline for seven years. However, the trial was abruptly halted, and when it resumed, her disease had progressed too far for the drug to be effective. Despite this setback, Geri and her husband continue to advocate for Alzheimer's patients and their caregivers, emphasizing the need for ethical treatment and increased research funding for the disease.

via Daily Mail|

#aducanumab #alzheimers #clinical-trial

health2 years ago•3 min saved

"Targeting Immune Cell Exhaustion to Combat Alzheimer's Neurodegeneration"

New research suggests that exhausted immune cells in the brain, known as TIM, may play a key role in driving Alzheimer's disease, particularly in individuals with the APOE4 gene variant. The study found that these immune cells lose their ability to efficiently remove plaque from the brain, contributing to Alzheimer's. Additionally, the Alzheimer's drug aducanumab was found to improve the condition of these exhausted cells, particularly in mice with the APOE4 variant. The findings may lead to the development of novel Alzheimer's therapies targeting these exhausted immune cells.

via The Rockefeller University|

#aducanumab #alzheimers #apoe4-gene-variant

healthscience2 years ago•4 min saved

"Alzheimer's Drug Successfully Penetrates Brain Barrier Using Sound Waves: Study"

A small study has shown that using focused ultrasound to open the blood-brain barrier is safe and may help Alzheimer's medications reach the brain more effectively. The study involved three patients who received monthly doses of the Alzheimer's drug aducanumab, with one hemisphere of their brains receiving the medication along with focused ultrasound. The treated hemisphere showed a 32% reduction in harmful amyloid beta plaques compared to the untreated hemisphere. While the technique shows promise, further research is needed to understand its long-term effects and potential side effects.

via The Washington Post|

#aducanumab #alzheimers #blood-brain-barrier

neurology2 years ago•4 min saved

Limited Eligibility for Lecanemab in Early Alzheimer's Patients

Only a small percentage of individuals with early Alzheimer's disease meet the eligibility criteria for the anti-amyloid monoclonal antibody treatments lecanemab and aducanumab, according to data from the Mayo Clinic Study of Aging. The study found that out of 237 participants with mild cognitive impairment or mild dementia and increased brain amyloid, only 8% qualified for a lecanemab trial and 5.1% qualified for an aducanumab trial. The researchers noted that the strict criteria, which include chronic health conditions and brain scan abnormalities, limit the number of eligible candidates. Further research is needed to assess the safety and efficacy of these treatments in larger and more diverse populations before they can be widely available to Alzheimer's patients.

via Medpage Today|

#aducanumab #alzheimers-disease #clinical-trials